Novo Nordisk A/S (NYSE:NVO) Shares Bought by Montag A & Associates Inc.

Montag A & Associates Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 1.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 9,492 shares of the company’s stock after buying an additional 96 shares during the period. Montag A & Associates Inc.’s holdings in Novo Nordisk A/S were worth $982,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. U.S. Capital Wealth Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 0.6% during the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock valued at $1,595,000 after buying an additional 90 shares during the period. Clarius Group LLC boosted its stake in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after purchasing an additional 93 shares during the period. Tradewinds Capital Management LLC grew its holdings in Novo Nordisk A/S by 2.0% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after purchasing an additional 95 shares in the last quarter. 9258 Wealth Management LLC lifted its holdings in Novo Nordisk A/S by 4.0% in the 4th quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock worth $260,000 after buying an additional 97 shares in the last quarter. Finally, Relyea Zuckerberg Hanson LLC boosted its position in Novo Nordisk A/S by 3.2% in the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock valued at $327,000 after buying an additional 99 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE NVO traded down $0.25 during trading hours on Friday, hitting $128.41. The company had a trading volume of 3,079,899 shares, compared to its average volume of 3,983,050. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a market cap of $576.24 billion, a P/E ratio of 44.28, a price-to-earnings-growth ratio of 1.96 and a beta of 0.43. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The business has a fifty day simple moving average of $127.61 and a 200-day simple moving average of $113.70.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $133.60.

Get Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.